sPLA₂s are small enzymes (14–18 kDa) with calcium activation (Schaloske and Dennis, 2006). They contain highly conserved amino acid residues and sequences. All organisms express sPLA₂, including viruses (Farr et al., 2005), bacteria (Sato and Frank, 2004), plants (Ståhl et al., 1999), and invertebrates (Kishimura et al., 2000), where they exert various actions.

iPLA_2, PNPLA9, or iPLA₂β, is a calcium-independent PLA₂ that acts in membrane remodeling (Ackermann et al., 1994). The longest variant of iPLA₂ has a catalytic dyad of Ser/Asp and is comprised of seven ankyrin repeats, a linker region, and a patatin-like α/β hydrolase catalytic domain (Larsson Forsell et al., 1999).

cPLA₂ is classified into Group IVA of the PLA₂ superfamily (Clark et al., 1991). It is an 85 kDa protein and regulated by intracellular calcium. This enzyme is widely distributed in cells throughout most types of human tissues and consists of two functional domains C2 and α/β hydrolase. Calcium-binding to the C2 domain causes translocation of the protein to a PL membrane (Channon and Leslie, 1990). cPLA₂ catalyzes AA release from various PLs and has lysophospholipase and trans-acylase activities (Reynolds et al., 1991).

Platelet-activating factor (PAF) is a potent PL mediator that plays a major role in clotting and inflammatory pathways (Prescott et al., 2000). LpPLA₂ catalyzes the hydrolysis of the sn-2 fatty acid in PAF or other lipid substrate and is thus called PAF acetyl hydrolase (PAF-AH; Tjoelker et al., 1995; Stafforini et al., 1997).

Group XVI PLA₂ is AdPLA₂ abundant in adipose tissue (Duncan et al., 2008) and acts in lipolysis via the production of eicosanoid mediators (Jaworski et al., 2009).

Like vertebrates, PLA₂ activity acts in lipid digestion, metabolism, secretion, reproduction, and immunity in insects (Stanley, 2006a). Three types of PLA₂s are detected in insects (Table 1). In lipid digestion, PLA₂ performs two crucial roles by direct hydrolysis of dietary PLs at the sn-2 position to generate nutritionally essential PUFAs and by providing lysophospholipids as insect “bile salts” that solubilize dietary neutral lipids for digestion by other lipases (Stanley, 2006b). The predatory tiger beetle, Cicindella circumpicta expresses a midgut calcium-dependent PLA₂ activity (Uscian et al., 1995). Protein fractionation indicated that the enzyme activity was detected in low molecular weight range (about 22 kDa), suggesting a sPLA₂. Manduca sexta secretes PLA₂ activity from midgut in vitro cultures and catalyzes AA release from PL (Rana et al., 1998; Rana and Stanley, 1999). Larvae of the mosquitoes Aedes aegypti, A. albopictus, and Culex quinquefasciatus express midgut PLA₂ activity (Nor Aliza and Stanley, 1998; Abdul Rahim et al., 2018). The peaks of the enzyme activity followed feeding cycles of the mosquito larvae. Similar iPLA₂-like activity comes from salivary gland of M. sexta (Tunaz and Stanley, 2004). Burying beetles, Nicrophorus marginatus, inter small mammals as larval food and express a salivary PLA₂ to protect the bodies from decomposition during larval development (Rana et al., 1997). Ryu et al. (2003) characterized a gene encoding a D. melanogaster PLA₂, which increased interest in insect PLA₂s.

Recent work by Sadekuzzaman and Kim (2017) using specific PLA₂ inhibitors supports the concept of multiple PLA₂ activities in several tissues of larval Spodoptera exigua. Vatanparast et al. (2018) recorded cellular PLA₂ activity in S. exigua plasma which is enhanced in response to immune challenge.

All venomous sPLA₂s are clustered into the Group III in PLA₂s. Similar sPLA₂s were predicted from Tribolium castaneum genome (Shrestha et al., 2010). Five sPLA₂s encode 173–261 amino acids, in which eight cysteines are conserved. We infer the enzyme is stabilized by formation of four disulfide bonds. All five sPLA₂s are expressed in different developmental stages of T. castaneum. Among them, four PLA₂s are associated with cellular immune functions. Two sPLA₂ genes are encoded and expressed in a hemipteran insect, R. prolixus (Defferrari et al., 2014). These are named as Rhopr-PLA2III and Rhopr-PLA2XII because they have Group III and XII-specific active site sequences of “C-C-R-T-H-D-L-C” and “C-C-N-E-H-D-I-C,” respectively. Both sPLA₂ genes are expressed in most nymphal tissues (especially salivary gland) of R. prolixus, in which Rhopr-PLA2XII was more highly expressed than Rhopr-PLA2III.

The first lepidopteran non-venom sPLA₂ was identified from S. exigua (Vatanparast et al., 2018), which encodes 194 amino acids containing three domains, a signal peptide, a calcium-binding domain, and a catalytic site. This enzyme clusters with other Group III sPLA₂s. Though all insect sPLA₂s are clustered in Group III, venomous and non-venomous sPLA₂s are distinct in amino acid sequences (Figure 2). Venomous sPLA₂s have more cysteine residues than their non-venomous counterparts, which they may need more stable structures to sustain enzyme activity in external environments (Kim et al., 2018).

As seen in the Tribolium and Spodoptera systems, sPLA₂s are likely to mediate immune responses via AA release because RNA interference (RNAi)-treated larvae exhibited significant immunosuppression and AA treatments rescued the immune responses (Shrestha et al., 2010; Vatanparast et al., 2018). An additional sPLA₂ immune function may be its direct antibacterial activity in hemolymph. In mammals, Group IIa sPLA₂ is one of the most effective antibacterial agents by hydrolyzing the bacterial membrane PLs (Wu et al., 2010).

Park et al. (2015a) reported an insect iPLA₂ in S. exigua (SeiPLA₂A). SeiPLA₂A encodes a protein with 816 amino acids with a predicted molecular weight of 90.5 kDa. SeiPLA₂A clusters with Group VIA, which is characterized by multiple ankyrin repeats in the N-terminal region with a consensus lipase motif (“GTSTG”) in the C-terminal region (Winstead et al., 2000). SeiPLA₂A was localized in cytoplasm by an immunofluorescence assay. dsSeiPLA₂A treatments suppressed gene expression and enzyme activity and led to two pathological phenotypes, loss of cellular immune response and extended larval-to-pupal development. Another iPLA₂, denoted SeiPLA₂B, was identified in S. exigua (Sadekuzzaman et al., 2017). This enzyme differs from SeiPLA₂A in several fundamental ways. SeiPLA₂B is a small iPLA₂, encoding 336 amino acids with a predicted size of about 36.6 kDa. It lacks ankyrin repeats in the N-terminal region. SeiPLA₂B clusters with Group VIF. Both SeiPLA₂A and SeiPLA₂B are expressed in all developmental stages. The insect iPLA₂s are separated into ankyrin and non-ankyrin types (Figure 3). An iPLA₂ gene was also identified from another lepidopteran insect, Bombyx mori (Orville Singh et al., 2016) and it is rich in glycine-histidine repeats. This iPLA₂ is highly expressed in fat body and RNAi treatments led to severe abnormal development and mortality.

A molecular signature of vertebrate cPLA₂ is the C2 domain, responsible for calcium-dependent translocation of the enzyme to membranes (Nalefski et al., 1998), which has not been recorded in insects. Variation of PLA₂ types were analyzed in S. exigua in different developmental stages and tissues (Sadekuzzaman and Kim, 2017). All developmental stages have significant PLA₂ activities. Among larval tissues, hemocytes had higher PLA₂ activities than fat body, gut, or epidermis. Different tissues of fifth instar larvae exhibited variation in susceptibility to inhibitors, with epidermal tissue sensitive to cPLA₂ inhibitor alone while other tissues are sensitive to all three inhibitor types. The variation of PLA₂ types in a one species may offer differential mediation of immune functionalities via eicosanoid signaling. In S. exigua plasmatocytes, intracellular calcium ion is required for cell spreading, which is inhibited by a calcium chelator (Srikanth et al., 2011). In M. sexta, PLA₂ activity in the cytosolic fraction was significantly inhibited by treatment with a cPLA₂-specific inhibitor, methyl arachidonyl fluorophosphate (Park et al., 2005). We infer insect cPLA₂s occur in a novel molecular form.

Eicosanoids transmit non-self recognition to hemocytes and fat body for systemic immune responses (Stanley and Kim, 2014). Blocking eicosanoid biosynthesis would be a highly effective immunosuppressive strategy in entomopathogen-insect interactions (Kim et al., 2018). This pathogenic strategy is used by some entomopathogens. One example is Trypanosoma rangeli, which is a mammalian parasite transmitted by the bite of triatomid bugs, Rhodnius, and Triatoma (Groot, 1952). The parasites develop within the insect hemolymph and then make their way to the salivary glands for the transmission. In R. prolixus, T. rangeli suppresses hemocyte phagocytosis by suppressing PLA₂ activity to inhibit eicosanoid biosynthesis (Figueiredo et al., 2008). Indeed, the addition of AA prevented the parasite infection. Another example is reported in two genera of entomopathogenic bacteria, Xenorhabdus and Photorhabdus (Kim et al., 2005). These bacteria are symbionts of entomopathogenic nematodes (EPNs) in the Steinernematidae and Heterorhabditidae (Gaugler, 2002; Shapiro-Ilan et al., 2012). After infective juvenile (IJ) nematodes enter host insects, they release symbiotic bacteria into host hemocoel (Forst et al., 1997), which rapidly induces immunosuppression in their hosts (Park and Kim, 2000, 2003). Subsequently, the nematodes develop and reproduce in the insect cadaver (Akhurst, 1980). To induce the host immunosuppression, Xenorhabdus and Photorhabdus inhibit PLA₂ activity to block eicosanoid biosynthesiss (Kim et al., 2005). In pioneering research with X. nematophila and their symbiont EPN, S. carpocapsae, Park and Kim (2000) injected the bacteria into S. exigua. They explored the hypothesis that bacterial factors act to suppress insect immunity by inhibiting eicosanoid biosynthesis. In their first test of the hypothesis, they injected AA into bacterial-infected larvae, which rescued the insect immune responses. They also injected the PLA₂ inhibitor, dexamethasone (DEX) which substantially increased the bacterial virulence. This led to another hypothesis that bacterial secretions inhibit PLA₂ activity and all downstream biosynthesis of eicosanoids. The authors used a quantifiable, specific immune function, hemocyte nodule formation (nodulation), to monitor the change in immune response after bacterial challenge. Injection of heat-killed X. nematophila induced about 57 nodules per larva, compared to the same treatment with live X. nematophila, with less than 10 nodules, indicating substantial reduction in the cellular immunity. Injecting AA increased nodulation in the larvae treated with live X. nematophila. Therefore, the authors inferred that two genera of entomopathogenic bacteria, Xenorhabdus and Photorhabdus inhibit PLA₂ to induce host immunosuppression (Kim et al., 2005). Several commercial sPLA₂ preparations from porcine pancreas, honey bee venom, and snake (Naja mossambica) venom were strongly inhibited by an organic extract of the Xenorhabdus culture broth (Park et al., 2004). To test the bacterial extract on insect sPLA₂ activity, an immune-associated sPLA₂ from T. castaneum was overexpressed, and it was inhibited by the bacterial extract (Shrestha and Kim, 2009). We propose the principle that host nematodes and their symbiotic bacteria suppress insect host immune responses by inhibiting PLA₂ activity to optimize their pathogenicity. Ahmed and Kim (2018) supports the idea with their report of a functional correlation between the bacterial virulence and its inhibitory intensity against host PLA₂ activity.

Production of multiple PLA₂ inhibitors by the bacteria is more nuanced that first thought because the inhibitors are produced in a sequential pattern during bacterial growth and they exert additional inhibitory activities against different immune responses (Eom et al., 2014). They identified seven bacterial secondary metabolites, in which benzylideneacetone and a dipeptide (pro-tyr) are the most potent to inhibit PLA₂. Though other five bacterial compounds can inhibit PLA₂, they exhibit high inhibitory activities against PO enzyme activity or hemolytic activity to lead to insect immunosuppression (Seo et al., 2012). Because these bacterial secondary metabolites are produced at different bacterial growth phases, we infer that X. nematophila sequentially produces them to sequentially and cooperatively inhibit different steps of insect immune responses, including PLA₂ activity.

The entomopathogens also inhibit the direct PLA₂-mediated antibacterial activity. In S. exigua, the hemolymph from naïve larvae exhibits high sPLA₂ activity, which is further increased in response to bacterial immune challenge (Vatanparast et al., 2018). Thus, we propose that Xenorhabdus and Photorhabdus bacteria released from host nematodes inhibit sPLA₂ in the hemolymph to protect themselves from antibacterial enzyme activity and suppress insect immunity.

Loher (1979) injected 50 mg PGE₂ into virgin female crickets, Teleogryllus commodus, and observed more than fourfold increase in oviposition behavior compared to saline-injected controls. He concluded that PGE₂ is an oviposition stimulant, noting that the PG action site was unknown, possibly via direct action on ovaries or muscles involved in oviposition. We will see that neither was correct.

Loher and his colleagues investigated the point in more detail (Loher et al., 1981). They found about 500 pg PGE₂ in spermathecae from mated, but not virgin females. Spermathecae contained far less PGE₂, about 20 pg/spermatophore. They found that spermatophores and spermathecae from mated, but not virgin, females biosynthesized about 25–35 pmol PGE₂/h/gland and smaller amounts of PGF_2α. This became the basis of the “enzyme transfer” model, in which a PG biosynthesis activity is transferred to females via spermatophores. Within spermathecae, the transferred enzyme activity converts AA into PGE₂, which is released into hemolymph circulation. The precise target of the PGE₂ remains unknown, although the PGs may interact with a specific receptor located in the terminal abdominal ganglion, the site of the egg-laying behavioral program.

Lange (1984) reported the transfer of PG synthase activity during mating in Locusta migratoria. Mating led to a fourfold increase in PG biosynthesis, compared to virgins, in spermathecal preparations. Mating, but not PG treatments, led to substantial increases in egg laying. Similarly, Brenner and Bernasconi (1989) recorded the presence of AA and PG biosynthesis in spermatophores and testes of the hematophagous kissing bug, Triatoma infestans. The PG synthase activity is transferred to females during mating because there was PGE₂ synthase activity in spermatophores and a low enzyme activity in spermathecae from mated, but not virgin, bugs. The authors speculated the PGs release egg-laying behavior in T. infestans.

PGs release egg-laying behavior in an unknown number of insect species, certainly not all and not even all cricket species. Lee and Loher (1995) reported that treating short-tailed crickets, Anurogryllus muticus with PGs did not influence oviposition behavior. Nonetheless, releasing egg-laying behavior is one of several PG actions in insect reproduction.

Machado et al. (2007) investigated the idea that PG signaling acts in follicle development in silk moth, B. mori. Incubating follicular epithelial cells in the presence of PG biosynthesis inhibitors, aspirin and, separately, indomethacin, blocked transition from follicle development to choriogenesis. They suggested the PGs act in follicle homeostatic physiology, rather than signaling a more specific developmental step.

Tootle and Spradling (2008) used in vitro follicle cultures prepared from D. melanogaster to show that stage 10B egg chamber maturation is inhibited in a dose-related manner by the presence of aspirin or the selective COX-2 inhibitor, NS-398. Treating follicles with PGH₂ partially rescued development. Noting that mammalian COXs may have evolved from heme-dependent peroxidases, the authors identified a Drosophila peroxidase, Pxt, which produces PGs in a COX-like manner. They also advanced thinking about PG actions beyond general homeostasis to identification of a specific PG action in the actin cytoskeleton within ovarian follicles (Spracklen et al., 2014).

Tootle and her colleagues found more than 150 genes are expressed in specific stages during the final day of follicle development (Tootle et al., 2011), including known and new genes encoding egg shell proteins. Mutations in the Drosophila Pxt and RNAi treatments lead to mis-timed appearance of transcripts encoding egg shell proteins and defective egg shells.

The biological significance of the work on Drosophila follicle development lies in Drosophila as a model of insect and mammalian molecular processes, which teaches that these molecular processes are very basic biological events. They likely occur in most, if not all, animals. Here, we pose this as a recurrent theme, indicating that some PG actions recorded in insects are fundamental actions in virtually all insects, and likely arthropod, species.

Steele and his colleagues investigated the biology of hypertrehalocemic hormones (HTH-I and -II). Their model was composed of disaggregated trophocytes prepared by treating fat bodies isolated from the cockroach, Periplaneta americana, with collagenase. HTH treatments led to increased concentrations of free fatty acids in the trophocytes. Treatments with the LOX inhibitor nordihydroguairaretic acid (NDGA) and COX-inhibitor (indomethacin: INDO) inhibited the release of free fatty acids. The authors inferred the free fatty acids, or their metabolites, act in synthesis and release of trehalose from trophocytes (Ali and Steele, 1997c). They later suggested the increased free fatty acid concentrations are regulated by PLA₂ and COX activities (Ali and Steele, 1997a). This is the first recognition that PG and other eicosanoid signaling mediate HTH actions. In direct testing of the idea that PGs act in trehalose synthesis in the isolated trophocytes, they treated separate preparations with HTH, 18:0, 18-1n-9, 18:2n-6, or AA, all of which created similar increases in trehalose synthesis. They also reported that HTH-I treatments led to increased biosynthesis of 20:3n-6 and 20:4n-6, which was blocked by INDO treatments and that treatments with PGF_2α, but not PGE₂, led to dose-related increases in trehalose efflux from the trophocytes (Ali and Steele, 1997b). The sugar efflux was inhibited by the COX inhibitors, indomethacin and diclofenac. A LOX inhibitor, NDGA and two PLA₂ inhibitors, mepacrine and 4′-bromophenacyl bromide (BPB), similarly led to decreased sugar efflux from HTH-I-treated fat body. Again, the authors inferred eicosanoids act in trehalose synthesis and efflux (Ali et al., 1998).

Sun and Steele (2002) reported that HTH-I and –II treatments substantially increased PLA₂ activity in membrane-enriched trophocyte preparations. The hormone effect, tested with HTH-II, was dose-dependent up to about 20 pmol/ml. Treating trophocytes with the PLA₂ inhibitor, BPB, over the range 0 to 1,000 μM, inhibited PLA₂ activity. The fat body PLA₂ activity may result from a cytosolic PLA₂ because HTH-II treatment led to translocation of the PLA₂ activity from the cytosol to the membrane fraction. This indicates Ca²⁺ is needed for translocation to the membrane and that the PLA₂ per se is Ca²⁺-independent. Their work documents PGs actions in homeostatic hormone signaling.

Stanley-Samuelson et al. (1991) posed the hypothesis that eicosanoids mediate insect immune responses to bacterial infection. They tested the hypothesis in a series of simple experiments based on treating tobacco hornworms, M. sexta, with an inhibitor of eicosanoid biosynthesis, DEX, and ethanol for controls and separately injecting them with a red-pigmented strain of the bacterium Serratia marcescens. They withdrew hemolymph samples over a 60-min time course, and recovered no bacteria in hemolymph from controls and increasing numbers of bacterial colonies from the DEX-treated insects. The DEX treatments led to dose-dependent decreases in insect survival, which were reversed in insects treated with AA. In light of the short timeframes of their experiments, the authors surmised that eicosanoid metabolism mediates some or all of the early immune responses in insects. These experiments opened a new research corridor on biochemical signaling in insect immunity.

Nodule formation of hemocytes is a cellular immune response to bacterial and other microbial infection (Dunn and Drake, 1983). Miller et al. (1994) reported that PGs and LOX products mediate formation of hemocyte microaggregates and melanotic nodules following S. marcescens infections. Hemocytes migrate toward sites of infection and wounding, where they act in host defense. Merchant et al. (2008) reported that eicosanoids mediate hemocyte migration. Phagocytosis is another cellular immune response by engulfing and secondary killing of invading microbes by phagocytic cells. PGE₂ stimulates phagocytosis in the greater wax moth, Galleria mellonella (Mandato et al., 1997), the beet armyworm, S. exigua (Shrestha and Kim, 2007) and the bug Rhodnius prolixus (Figueiredo et al., 2008). The secondary killing of engulfed microbes is driven by reactive oxygen species (ROS). Park et al. (2015b) demonstrated that eicosanoids mediate ROS production by activating NADPH-dependent oxidase (NOX), as seen also in vertebrates. We infer that both phases of phagocytosis, the engulfment and secondary killing of bacteria are mediated by eicosanoids. Upon infection by parasitoid eggs or EPNs, insects form several hemocyte layers around the relatively large size of pathogens to prevent oxygen or nutrient supply (Strand, 2008). Carton et al. (2002) showed that the hemocytic encapsulation is mediated by eicosanoids in D. melanogaster exposed to the endoparasitoid wasp, Leptopilina boulardi. Thus, eicosanoids are key mediators of insect cellular immunity (Stanley and Kim, 2014; Kim et al., 2018).

Humoral immune responses in insects include quinone melanization by phenoloxidase (PO) and killing microbes by antimicrobial peptides (AMPs) (Lemaitre and Hoffmann, 2007). In the S. exigua model, PGE₂ mediates release of inactive prophenoloxidase (PPO) from specific hemocytes (oenocytoids) into hemolymph by activating oenocytoid cell lysis (OCL) through a specific membrane receptor (Bos et al., 2004) that is expressed solely in oenocytoids in all life stages. Inhibiting expression of the S. exigua PGE₂ receptor led to reduced OCL and PO activity (Shrestha and Kim, 2008; Shrestha et al., 2011). PPO is activated into PO by enzymes in hemolymph, which initiates melanization, a key step in both humoral and cellular immune responses, and also in wound-healing response (Bidla et al., 2005). Indeed, a treatment of eicosanoid biosynthesis inhibitor (EBI) significantly suppressed clot formation around wounds of Drosophila larvae (Hyršl et al., 2011). EBI treatment inhibits expression of two AMP genes of B. mori against bacterial challenge (Morishima et al., 1997). In Drosophila, EBI specifically inhibits expression of AMP genes in IMD signal pathway (Yajima et al., 2003). In contrast, eicosanoids may mediate expression of AMP genes in both Toll/IMD pathways in the Oriental fruit fly, Bactrocera dorsalis (Li et al., 2017). In the fruit fly, a PLA₂ gene is linked with immune responses. Its RNAi treatment led to reduced gene expression of MyD88 and Relish along with suppressive expression of defensin (Toll pathway marker) and diptericin (IMD pathway marker). Similarly, both Toll/IMD signal pathways are controlled by EBI treatment in S. exigua, which led to significant suppression of AMP biosynthesis (Hwang et al., 2013). Thus, eicosanoids also mediate humoral immune responses in insects.

Eicosanoids mediating insect immune responses exhibit functional cross-talks with other immune mediators. Upon non-self recognition, immune mediators propagate the recognition signal to nearby immune effectors, hemocytes and fat body (Gillespie et al., 1997). These immune mediators include cytokines (small protein molecules, 5–20 kDa) such as the insect cytokine, plasmatocyte-spreading peptide (PSP; Clark et al., 1997), biogenic monoamines, nitric oxide (NO), and eicosanoids (Kim et al., 2018). Recent reports indicate that there is substantial cross-talk among immune mediators, in which eicosanoids play a crucial role in mediating most downstream signal (Figure 4).

Octopamine (OA) and serotonin (5-hydroxytryptophan: 5-HT) are biogenic monoamines that stimulate phagocytosis and nodulation in insects via the small G protein, Rac1 (Baines et al., 1992; Kim et al., 2009; Kim and Kim, 2010) through specific cell surface receptors (Dunphy and Downer, 1994; Qi et al., 2016). Phentolamine (an OA receptor antagonist) and ketanserin (a 5-HT receptor antagonist) suppress cellular immune responses of S. exigua in a competitive manner, and their inhibitory effects are reversed by an addition of AA (Kim et al., 2009). Eicosanoids are the downstream signals of the monoamines probably by increasing intracellular calcium concentrations as seen in the forest tent caterpillar moth, Malacosoma disstria (Jahagirdar et al., 1987) and by subsequently translocating cPLA₂ to its substrate PLs (Six and Dennis, 2000). Indeed, a PLA₂ of T. castaneum associated with immunity was translocated from cytosol to membrane in response to bacterial challenge (Shrestha et al., 2010).

The insect cytokine, PSP, is expressed as a proPSP in hemocytes and fat body (Clark et al., 1997) and cleaved into a 23 residue PSP that mediates plasmatocyte-spreading behavior in some plasmatocyte subpopulations (Clark et al., 1998). PSP is a member of the ENF peptide family which includes growth-blocking peptide (GBP) and paralytic peptides (PPs; Skinner et al., 1991). PSP induces cell-spreading via an approximately 190 kDa receptor (Clark et al., 2004), identified in Drosophila (Sung et al., 2017) as a Methuselah-like receptor-10 (Mthl10), for GBP. PSP mediates hemocyte-spreading behavior via cross-talk with other immune mediators (Kim et al., 2018). The effects of silencing the gene encoding proPSP were reversed by PSP or AA treatments (Srikanth et al., 2011). The PSP-stimulated hemocyte-spreading was impaired by inhibiting eicosanoid biosynthesis. Activation of eicosanoid biosynthesis by PSP or biogenic monoamines follows receptor-driven activation of Rac1. A Rac1 gene (SeRac1) that acts in cytoskeleton functions (Kim and Kim, 2010) was identified in S. exigua hemocytes (Park et al., 2013). Bacterial challenge up-regulated SeRac1 expression (by >37-fold) and silencing SeRac1 inhibited PSP- or biogenic monoamine-mediated hemocyte-spreading behavior. Injection of PGE₂ into SeRac1-silenced larvae rescued the influence of these immune mediators on hemocyte-spreading. PSP and biogenic amines increased PLA₂ activity, but not in hemocytes from SeRac1-silenced larvae. Therefore, we inferred that Rac1 transduces PSP and biogenic monoamine signaling by activating PLA₂ activity, which leads to eicosanoid biosynthesis. PSP and eicosanoids mediate PPO activation via eicosanoids (Park and Kim, 2014). OCL is required for the release of PPO into plasma, where it is activated (Jiang and Kanost, 2000). In S. exigua, PO is activated by PGs, which mediate OCL to release PPO (Shrestha and Kim, 2008). PSP induces PPO activation in S. exigua (Park and Kim, 2014), suggesting that PG acts downstream of PSP for PPO activation. Injection of PGE₂ to the larvae treated with DEX rescued the PPO activation. Park et al. (2013) reported that Rac1 facilitates cross-talk between PSP and eicosanoids. In S. exigua Rac1 activates PLA₂ for PG biosynthesis. The PPO induction period by PGE₂ treatment was significantly reduced in Rac1-silenced larvae. This reduction of PPO activation by PSP silencing is explained by the absence of endogenous PSP to sustain PLA₂ activation for PG biosynthesis. Thus, PSP requires PGE₂ as a downstream mediator of PPO activation.

Cross-talk between PSP and eicosanoids acts in down-regulation of PPO activation during later infection stages (Park and Kim, 2014). A specific PSP-binding protein (PSP-BP) terminates the PSP activation of PO because RNAi silencing of PSP-BP extended the PPO activation period (Park and Kim, 2014). This explains how eicosanoids mediate both activation and inactivation of PPO.

NO is a small, membrane-permeable signal molecule that acts in nervous and immune systems in insects and vertebrates (Rivero, 2006). NO is synthesized from L-arginine by NO synthase (NOS), which in mammals exists in three forms (Colasanti et al., 2002). NO mediates immunity in mosquitoes, defending them from malarial parasites (Dimopoulos et al., 1998; Luckhart et al., 1998). In M. sexta, RNAi suppressed NOS expression showed that NO is directly associated with immunity (Eleftherianos et al., 2009). Cross-talk between cytokine and NO signaling induces AMP gene expression in B. mori, where a PSP-like cytokine elevates NO concentration by inducing NOS expression (Ishii et al., 2013). Sadekuzzaman et al. (2018) showed that bacterial injection increased NO concentrations in larval hemocytes and fat body and that silencing a S. exigua nitric oxide synthase (SeNOS) gene suppressed NO concentrations. The silencing of SeNOS expression and, separately, injecting L-NAME (a specific NOS inhibitor) led to reduced PLA₂ activities in hemocytes and fat body relative to controls. Injecting a NO donor, S-nitroso-N-acetyl-DL-penicillamine, increased PLA₂ activity in a dose-dependent manner. Eicosanoids did not influence NO concentrations in immune challenged larvae, from which it can be inferred that eicosanoid signaling is downstream to NO signaling.

NO treatments alone led to AMP induction because injection of an NO analog, SNAP, without bacterial challenge induced AMP gene expression (Sadekuzzaman and Kim, 2018). There is an additional line of cross-talk between the Toll/IMD pathways and NO signaling because RNAi of Toll or IMD signal components led to reduced levels of NO by inhibiting NOS expression in S. exigua (Sadekuzzaman and Kim, 2018). We infer that Toll/IMD signaling triggers NO signaling, which activates PLA₂ to synthesize eicosanoids. In addition, a recent study (Shafeeq et al., 2018) showed that two Toll signal components (MyD88 and Pelle) activate PLA₂ in S. exigua, suggesting a direct cross-talk between Toll and eicosanoid signal pathways.